Prognosis

Astra Delivers But Can’t Match Rivals. Here’s What We Know

AstraZeneca Says Too Early to Speculate on Vaccine Regulation
Lock
This article is for subscribers only.

The pressure was on AstraZeneca Plc and the University of Oxford after stunning Covid-19 vaccine trial results from Pfizer Inc. and Moderna Inc., and the U.K. partners delivered, even if they couldn’t match the data from the two front-runners.

Scientists will now closely scrutinize the preliminary resultsBloomberg Terminal. The report is significant because Astra and Oxford are taking a different approach from the one used by Pfizer and Moderna, and vaccine advocates say multiple shots will be needed to stop a contagion that’s killed almost 1.4 million people. Here’s what we know, and what the results could mean in the battle.